Lansen Pharmaceutical Holdings Limited
HKEX:0503.HK
1.79 (HKD) • At close November 28, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 65.558 | 54.18 | 54.386 | 54.257 | 56.872 | 89.484 | 94.824 | 93.349 | 116.817 | 95.074 | 93.844 | 74.475 | 58.607 | 47.932 | 37.119 | 24.15 |
Cost of Revenue
| 21.263 | 19.771 | 19.207 | 20.928 | 26.601 | 37.595 | 41.048 | 45.386 | 54.346 | 42.836 | 39.42 | 30.088 | 20.174 | 15.493 | 11.094 | 7.695 |
Gross Profit
| 44.295 | 34.409 | 35.179 | 33.329 | 30.271 | 51.889 | 53.776 | 47.963 | 62.471 | 52.238 | 54.424 | 44.387 | 38.433 | 32.439 | 26.025 | 16.455 |
Gross Profit Ratio
| 0.676 | 0.635 | 0.647 | 0.614 | 0.532 | 0.58 | 0.567 | 0.514 | 0.535 | 0.549 | 0.58 | 0.596 | 0.656 | 0.677 | 0.701 | 0.681 |
Reseach & Development Expenses
| 2.132 | 2.686 | 4.287 | 6.501 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 9.63 | 12.224 | 7.935 | 15.26 | 15.875 | 12.83 | 17.432 | 12.228 | 13.661 | 11.97 | 9.828 | 8.67 | 7.024 | 5.546 | 4.224 | 5.247 |
Selling & Marketing Expenses
| 19.458 | 17.366 | 15.668 | 18.042 | 17.11 | 30.873 | 29.279 | 27.176 | 33.497 | 27.733 | 31.258 | 24.796 | 20.429 | 18.143 | 14.809 | 10.226 |
SG&A
| 29.088 | 29.59 | 23.603 | 33.302 | 32.985 | 43.703 | 46.711 | 39.404 | 47.158 | 39.703 | 41.086 | 33.466 | 27.453 | 23.689 | 19.033 | 15.473 |
Other Expenses
| -1.465 | -1.056 | 0.209 | -3.478 | 0.1 | -4.637 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 29.755 | 28.534 | 23.812 | 29.824 | 29.274 | 43.028 | 45.149 | 35.296 | 44.001 | 37.511 | 38.543 | 30.721 | 25.481 | 22.869 | 18.555 | 14.845 |
Operating Income
| 14.158 | 8.77 | 12.852 | 3.959 | -0.587 | 9.456 | 9.185 | 13.824 | 18.922 | 15.144 | 16.169 | 15.607 | 13.173 | 9.57 | 7.47 | 1.61 |
Operating Income Ratio
| 0.216 | 0.162 | 0.236 | 0.073 | -0.01 | 0.106 | 0.097 | 0.148 | 0.162 | 0.159 | 0.172 | 0.21 | 0.225 | 0.2 | 0.201 | 0.067 |
Total Other Income Expenses Net
| -4.243 | -6.366 | 78.55 | 14.683 | -0.191 | 7.589 | -2.159 | -9.493 | -0.854 | -0.063 | 0.397 | -0.459 | -0.388 | -0.667 | -1.518 | -0.774 |
Income Before Tax
| 9.915 | 2.404 | 91.402 | 18.642 | 2.09 | 17.045 | 7.026 | 4.331 | 18.068 | 15.081 | 16.566 | 15.148 | 12.785 | 8.903 | 5.952 | 0.836 |
Income Before Tax Ratio
| 0.151 | 0.044 | 1.681 | 0.344 | 0.037 | 0.19 | 0.074 | 0.046 | 0.155 | 0.159 | 0.177 | 0.203 | 0.218 | 0.186 | 0.16 | 0.035 |
Income Tax Expense
| 1.318 | 1.501 | 3.197 | 0.293 | 1.93 | 1.416 | 3.19 | 2.26 | 4.088 | 3.39 | 2.568 | 2.695 | 2.572 | 1.523 | 0.879 | 0.404 |
Net Income
| 8.597 | 0.903 | 88.205 | 18.349 | 0.16 | 15.629 | 3.836 | 2.071 | 13.98 | 11.691 | 13.998 | 12.453 | 10.213 | 7.38 | 5.073 | 0.432 |
Net Income Ratio
| 0.131 | 0.017 | 1.622 | 0.338 | 0.003 | 0.175 | 0.04 | 0.022 | 0.12 | 0.123 | 0.149 | 0.167 | 0.174 | 0.154 | 0.137 | 0.018 |
EPS
| 0.021 | 0.002 | 0.21 | 0.044 | 0 | 0.036 | 0.009 | 0.005 | 0.033 | 0.027 | 0.033 | 0.029 | 0.026 | 0.024 | 0.016 | 0.001 |
EPS Diluted
| 0.021 | 0.002 | 0.21 | 0.044 | 0 | 0.036 | 0.009 | 0.005 | 0.033 | 0.027 | 0.033 | 0.029 | 0.026 | 0.024 | 0.016 | 0.001 |
EBITDA
| 15.258 | 11.66 | 18.412 | 9.181 | 6.019 | 14.331 | 14.086 | 19.386 | 24.358 | 19.178 | 19.735 | 17.244 | 14.282 | 10.482 | 8.281 | 2.083 |
EBITDA Ratio
| 0.233 | 0.215 | 0.339 | 0.169 | 0.106 | 0.16 | 0.149 | 0.208 | 0.209 | 0.202 | 0.21 | 0.232 | 0.244 | 0.219 | 0.223 | 0.086 |